Search research articles
Contact Us
Filters
Showing results (141-150 of 187) with videos related to
Page
of 19
Sort By:
British Journal of Haematology
|
February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study
Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Clinical Pharmacology and Therapeutics
|
November 7, 2021
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
Alberto Tosetto, Bianca Rocca, Giovanna Petrucci, et al.
European Journal of Haematology
|
July 20, 2024
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey
Bruno Fattizzo, Valentina Carrai, Monica Crugnola, et al.
British Journal of Haematology
|
July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology
|
July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
Valerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Blood
|
April 9, 2020
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Bianca Rocca, Alberto Tosetto, Silvia Betti, et al.
Nature Medicine
|
March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Page
of 19
Search research articles
Search
Showing results (141-150 of 187) with videos related to
Sort By:
Page
of 19
British Journal of Haematology
|
February 9, 2022
Deferasirox in the management of iron overload in patients with myelofibrosis treated with ruxolitinib: The multicentre retrospective RUX-IOL study
Elena Maria Elli, Ambra Di Veroli, Daniela Bartoletti, et al.
Annals of Hematology
|
January 20, 2025
Impact of calreticulin mutations on treatment and survival outcomes in myelofibrosis during ruxolitinib therapy
Francesca Palandri, Filippo Branzanti, Erika Morsia, et al.
Hematological Oncology
|
April 7, 2018
Epidemiology, outcome, and risk factors for infectious complications in myelofibrosis patients receiving ruxolitinib: A multicenter study on 446 patients
Nicola Polverelli, Giuseppe A Palumbo, Gianni Binotto, et al.
Clinical Pharmacology and Therapeutics
|
November 7, 2021
Association of Platelet Thromboxane Inhibition by Low-Dose Aspirin With Platelet Count and Cytoreductive Therapy in Essential Thrombocythemia
Alberto Tosetto, Bianca Rocca, Giovanna Petrucci, et al.
European Journal of Haematology
|
July 20, 2024
Evans syndrome: Disease awareness and clinical management in a nation-wide ITP-NET survey
Bruno Fattizzo, Valentina Carrai, Monica Crugnola, et al.
British Journal of Haematology
|
July 17, 2018
Ruxolitinib in elderly patients with myelofibrosis: impact of age and genotype. A multicentre study on 291 elderly patients
Francesca Palandri, Lucia Catani, Massimiliano Bonifacio, et al.
Annals of Hematology
|
July 18, 2025
Exploring thromboembolic risk factors in polycythemia vera: from current evidence to PROSPERO study design
Valerio De Stefano, Francesco Passamonti, Francesca Palandri, et al.
Hematological Oncology
|
April 10, 2020
Risk factors for progression to blast phase and outcome in 589 patients with myelofibrosis treated with ruxolitinib: Real-world data
Francesca Palandri, Massimo Breccia, Mario Tiribelli, et al.
Blood
|
April 9, 2020
A randomized double-blind trial of 3 aspirin regimens to optimize antiplatelet therapy in essential thrombocythemia
Bianca Rocca, Alberto Tosetto, Silvia Betti, et al.
Nature Medicine
|
March 11, 2025
Pelabresib plus ruxolitinib for JAK inhibitor-naive myelofibrosis: a randomized phase 3 trial
Raajit K Rampal, Sebastian Grosicki, Dominik Chraniuk, et al.
Page
of 19